Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Cervical human papilloma virus (HPV) DNA primary screening test: Results of a population-based screening programme in central Italy.
Passamonti B, Gustinucci D, Giorgi Rossi P, Cesarini E, Bulletti S, Carlani A, Martinelli N, Broccolini M, D'Angelo V, D'Amico MR, Di Dato E, Galeazzi P, Malaspina M, Spita N, Tintori B, Giaimo MD. Passamonti B, et al. Among authors: carlani a. J Med Screen. 2017 Sep;24(3):153-162. doi: 10.1177/0969141316663580. Epub 2016 Sep 10. J Med Screen. 2017. PMID: 27614992
Role of p16(INK4a) cytology testing as an adjunct to enhance the diagnostic specificity and accuracy in human papillomavirus-positive women within an organized cervical cancer screening program.
Gustinucci D, Passamonti B, Cesarini E, Butera D, Palmieri EA, Bulletti S, Carlani A, Staiano M, D'Amico MR, D'Angelo V, Di Dato E, Martinelli N, Malaspina M, Spita N, Tintori B, Fulciniti F. Gustinucci D, et al. Among authors: carlani a. Acta Cytol. 2012;56(5):506-14. doi: 10.1159/000338979. Epub 2012 Sep 27. Acta Cytol. 2012. PMID: 23075891
Use of Cytology, E6/E7 mRNA, and p16INK4a-Ki-67 to Define the Management of Human Papillomavirus (HPV)-Positive Women in Cervical Cancer Screening.
Gustinucci D, Giorgi Rossi P, Cesarini E, Broccolini M, Bulletti S, Carlani A, D'angelo V, D'amico MR, Di Dato E, Galeazzi P, Malaspina M, Martinelli N, Spita N, Tintori B, Giaimo MD, Passamonti B. Gustinucci D, et al. Among authors: carlani a. Am J Clin Pathol. 2016 Jan;145(1):35-45. doi: 10.1093/ajcp/aqv019. Am J Clin Pathol. 2016. PMID: 26712869
A comparative effectiveness trial of two faecal immunochemical tests for haemoglobin (FIT). Assessment of test performance and adherence in a single round of a population-based screening programme for colorectal cancer.
Passamonti B, Malaspina M, Fraser CG, Tintori B, Carlani A, D'Angelo V, Galeazzi P, Di Dato E, Mariotti L, Bulletti S, D'Amico MR, Gustinucci D, Martinelli N, Spita N, Cesarini E, Rubeca T, Giaimo M, Segnan N, Senore C. Passamonti B, et al. Among authors: carlani a. Gut. 2018 Mar;67(3):485-496. doi: 10.1136/gutjnl-2016-312716. Epub 2016 Dec 14. Gut. 2018. PMID: 27974550 Clinical Trial.
Expression of p16 in abnormal pap-tests as an indicator of CIN2+ lesions: a possible role in the low grade ASC/US and L/SIL (Ig) cytologic lesions for screening prevention of uterine cervical tumours.
Passamonti B, Gustinucci D, Recchia P, Bulletti S, Carlani A, Cesarini E, D'Amico MR, D'Angelo V, Di Dato E, Martinelli N, Malaspina M, Spita N. Passamonti B, et al. Among authors: carlani a. Pathologica. 2010 Feb;102(1):6-11. Pathologica. 2010. PMID: 20731248
Cervical Human Papilloma Virus (HPV) DNA Primary Screening Test Results of the Experience of a Regional Laboratory in Central Italy.
Passamonti BU, Bulletti S, Gustinucci D, Martinelli N, D'Amico MR, Spita N, Malaspina M, Carlani A, DI Dato E, Galeazzi P, Tintori B, D'angelo V, Calvi C. Passamonti BU, et al. Among authors: carlani a. Value Health. 2014 Nov;17(7):A614. doi: 10.1016/j.jval.2014.08.2162. Epub 2014 Oct 26. Value Health. 2014. PMID: 27202150 Free article. No abstract available.